CN113347975B - 用于治疗侵蚀性手骨关节炎的孟鲁司特 - Google Patents

用于治疗侵蚀性手骨关节炎的孟鲁司特 Download PDF

Info

Publication number
CN113347975B
CN113347975B CN201980089991.6A CN201980089991A CN113347975B CN 113347975 B CN113347975 B CN 113347975B CN 201980089991 A CN201980089991 A CN 201980089991A CN 113347975 B CN113347975 B CN 113347975B
Authority
CN
China
Prior art keywords
montelukast
pharmaceutically acceptable
acceptable salt
dose
osteoarthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980089991.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113347975A (zh
Inventor
若尔迪·蒙福特福雷
若塞普·韦尔热斯米拉诺
费尔南多·加西亚阿隆索
若尔迪·拉门托尔马萨纳
乔斯·安格尔·桑切斯加西亚
努里亚·桑斯梅内德斯
迈尔塔·维卡里奥德拉托雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmalider SA
Original Assignee
Mmc Intellectual Property Institute
Farmalider SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mmc Intellectual Property Institute, Farmalider SA filed Critical Mmc Intellectual Property Institute
Publication of CN113347975A publication Critical patent/CN113347975A/zh
Application granted granted Critical
Publication of CN113347975B publication Critical patent/CN113347975B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980089991.6A 2018-11-26 2019-11-25 用于治疗侵蚀性手骨关节炎的孟鲁司特 Active CN113347975B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382851 2018-11-26
EP18382851.6 2018-11-26
PCT/EP2019/082425 WO2020109230A1 (en) 2018-11-26 2019-11-25 Montelukast for the treatment of erosive hand osteoarthritis

Publications (2)

Publication Number Publication Date
CN113347975A CN113347975A (zh) 2021-09-03
CN113347975B true CN113347975B (zh) 2024-08-30

Family

ID=64665075

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089991.6A Active CN113347975B (zh) 2018-11-26 2019-11-25 用于治疗侵蚀性手骨关节炎的孟鲁司特

Country Status (22)

Country Link
US (1) US12539296B2 (enExample)
EP (1) EP3886857B1 (enExample)
JP (1) JP7399502B2 (enExample)
CN (1) CN113347975B (enExample)
AU (1) AU2019386235B2 (enExample)
BR (1) BR112021009980A2 (enExample)
CA (1) CA3120920C (enExample)
DK (1) DK3886857T3 (enExample)
ES (1) ES2961390T3 (enExample)
FI (1) FI3886857T3 (enExample)
HR (1) HRP20231283T1 (enExample)
HU (1) HUE063579T2 (enExample)
MA (1) MA54276B1 (enExample)
MD (1) MD3886857T2 (enExample)
MX (1) MX2021006209A (enExample)
MY (1) MY203365A (enExample)
PL (1) PL3886857T3 (enExample)
PT (1) PT3886857T (enExample)
RS (1) RS64668B1 (enExample)
SI (1) SI3886857T1 (enExample)
TW (1) TWI850283B (enExample)
WO (1) WO2020109230A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4228641A1 (en) * 2020-10-13 2023-08-23 Diomed Developments Limited Gel formulations comprising montelukast
GB2599912B (en) * 2020-10-13 2023-04-19 Diomed Dev Ltd New formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201020085D0 (en) * 2010-11-26 2011-01-12 Xaragen Pharma Ltd Methods and reagents for the treatment of arthritic disorders
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
527 MONTELUKAST SODIUM AS A TREATMENT FOR EXPERIMENTAL OSTEOARTHRITIS IN MICE;P.J. Fanning等;《Osteoarthritis and Cartilage》;第17卷(第S1期);第S282-283页 *

Also Published As

Publication number Publication date
MX2021006209A (es) 2021-08-11
SI3886857T1 (sl) 2023-12-29
PT3886857T (pt) 2023-10-25
HUE063579T2 (hu) 2024-01-28
RS64668B1 (sr) 2023-11-30
AU2019386235B2 (en) 2024-11-21
JP2022508236A (ja) 2022-01-19
TWI850283B (zh) 2024-08-01
US20220047570A1 (en) 2022-02-17
FI3886857T3 (fi) 2023-10-20
EP3886857A1 (en) 2021-10-06
CA3120920A1 (en) 2020-06-04
JP7399502B2 (ja) 2023-12-18
MD3886857T2 (ro) 2023-12-31
PL3886857T3 (pl) 2024-01-15
AU2019386235A1 (en) 2021-07-01
CA3120920C (en) 2024-01-02
DK3886857T3 (da) 2023-10-09
ES2961390T3 (es) 2024-03-11
WO2020109230A1 (en) 2020-06-04
US12539296B2 (en) 2026-02-03
EP3886857B1 (en) 2023-07-26
BR112021009980A2 (pt) 2021-08-17
HRP20231283T1 (hr) 2024-02-02
MY203365A (en) 2024-06-26
MA54276B1 (fr) 2023-11-30
TW202038954A (zh) 2020-11-01
CN113347975A (zh) 2021-09-03
MA54276A (fr) 2021-10-06

Similar Documents

Publication Publication Date Title
US12102637B2 (en) Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
JP2022540706A (ja) 鎮静作用のないデクスメデトミジン治療レジメン
US20190054088A1 (en) Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
US20130053448A1 (en) Therapeutic Regimens
KR20150139830A (ko) 신경변성 및 기타 질환의 치료를 위한 조성물 및 방법
CN113347975B (zh) 用于治疗侵蚀性手骨关节炎的孟鲁司特
AU2003287488B8 (en) Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
US20110319464A1 (en) Methods for treating benign prostatic hyperplasia
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
HK40054679A (en) Montelukast for the treatment of erosive hand osteoarthritis
HK40054679B (en) Montelukast for the treatment of erosive hand osteoarthritis
US20130143912A1 (en) Sublingual zolpidem formulations
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
KR20060123329A (ko) 월경 곤란증의 예방 및/또는 치료제
CN115279360A (zh) 局部用双氯芬酸组合物和方法
JP2023526337A (ja) 口腔咽頭真菌感染症を処置するための粘膜付着錠
BR112012030704B1 (pt) Composição farmacêutica de cocristais e processo para sua produção

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221213

Address after: Madrid

Applicant after: FARMALIDER S.A.

Address before: Madrid

Applicant before: MMC Intellectual Property Institute

GR01 Patent grant
GR01 Patent grant